Steven Bellon
Chief Tech/Sci/R&D Officer bij FOGHORN THERAPEUTICS INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Steven F.
Bellon is currently the Chief Scientific Officer at Foghorn Therapeutics, Inc. He previously worked as the Executive Director & Head-Structural Biology at Constellation Pharmaceuticals, Inc. from 2008 to 2016.
Dr. Bellon holds a doctorate degree from the Massachusetts Institute of Technology, which he obtained in 1992.
He also has an undergraduate degree from Haverford College, which he received in 1987.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-02-2024 | 171 957 ( 0.40% ) | 1 M $ | 31-03-2024 |
Actieve functies van Steven Bellon
| Bedrijven | Functie | Begin |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 10-01-2022 |
Eerdere bekende functies van Steven Bellon
| Bedrijven | Functie | Einde |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 01-05-2016 |
Opleiding van Steven Bellon
| Massachusetts Institute of Technology | Doctorate Degree |
| Haverford College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
